Corcept Therapeutics Inc [CORT] stock is trading at $74.17, up 0.95%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CORT shares have gain 2.22% over the last week, with a monthly amount drifted -15.86%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on November 06, 2023, when Truist upgraded its rating to a Buy and also boosted its price target to $38 from $29. Previously, SVB Securities started tracking the stock with Market Perform rating on April 11, 2023, and set its price target to $25. On April 04, 2023, Piper Sandler initiated with an Overweight rating and assigned a price target of $27 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $22 on February 15, 2023. Truist downgraded its rating to a Hold but $30 remained the price target by the analyst firm on August 01, 2022. Jefferies upgraded its rating to Buy for this stock on July 27, 2022, and upped its price target to $35.
Corcept Therapeutics Inc [CORT] stock has fluctuated between $46.38 and $117.33 over the past year. Currently, Wall Street analysts expect the stock to reach $140 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $74.17 at the most recent close of the market. An investor can expect a potential return of 88.76% based on the average CORT price forecast.
Analyzing the CORT fundamentals
Corcept Therapeutics Inc [NASDAQ:CORT] reported sales of 716.08M for the trailing twelve months, which represents a growth of 18.70%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.14%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.19%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.2 and Total Capital is 0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 71.69 points at the first support level, and at 69.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 75.46, and for the 2nd resistance point, it is at 76.75.
Ratios To Look Out For
For context, Corcept Therapeutics Inc’s Current Ratio is 3.06. In addition, the Quick Ratio stands at 2.98 and the Cash Ratio stands at 0.71. Considering the valuation of this stock, the price to sales ratio is 10.91, the price to book ratio is 12.28 and price to earnings (TTM) ratio is 66.01.
Transactions by insiders
Recent insider trading involved BELANOFF JOSEPH K, Officer, that happened on Nov 03 ’25 when 40000.0 shares were purchased. Officer, Lyon Joseph Douglas completed a deal on Nov 03 ’25 to buy 5000.0 shares. Meanwhile, Officer Maduck Sean bought 20000.0 shares on Nov 03 ’25.
